EIF2S1: A Drug Target / Disease Biomarker (G1965)

Target Name: EIF2S1

NCBI ID: G1965

EIF2S1

EIF2S1: A Drug Target / Disease Biomarker

EIF2S1, also known as EIF2S1 gene or protein, is a protein that is expressed in various tissues of the body. It is a key regulator of the essential elastin gene, which is responsible for the production of elastin, a protein that is involved in many physiological processes in the body. Mutations in the EIF2S1 gene have been linked to a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and diseases of the skin. As a result, EIF2S1 has become a focus of research in the field of genetics and has potential as a drug target or biomarker.

The EIF2S1 gene is located on chromosome 12 and encodes a protein that is composed of 218 amino acids. The protein has several important functions, including regulating the activity of other genes, cell signaling, and tissue structure. EIF2S1 is also involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs.

One of the key functions of EIF2S1 is its role in regulating the production of elastin. Elastin is a protein that is involved in many physiological processes in the body, including the maintenance of posture, the formation of blood vessels, and the development of bones and skin. It is produced by cells called chondrocytes, which are specialized cells that produce collagen, a protein that is involved in tissue structure and integrity.

In humans, mutations in the EIF2S1 gene have been linked to a variety of diseases. For example, mutations in the EIF2S1 gene have been linked to the development of conditions such as Marfan syndrome, a genetic disorder that affects the body's connective tissue, and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its role in the production of elastin, EIF2S1 is also involved in the regulation of cell signaling. It has been shown to play a role in the regulation of cell proliferation and differentiation, and has been linked to the development of cancer. Additionally, EIF2S1 is involved in the regulation of cell adhesion and has been shown to play a role in the development of tissues and organs.

As a result of its involvement in so many physiological processes, EIF2S1 has potential as a drug target or biomarker. For example, studies have shown that blocking the activity of EIF2S1 has potential as a treatment for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, research has suggested that EIF2S1 may be a useful biomarker for monitoring the effectiveness of cancer treatments.

In conclusion, EIF2S1 is a protein that is expressed in various tissues of the body and is involved in the regulation of many important physiological processes. Its role in the production of elastin and the regulation of cell signaling makes it a potential drug target or biomarker. Further research is needed to fully understand the functions of EIF2S1 and its potential as a therapeutic agent.

Protein Name: Eukaryotic Translation Initiation Factor 2 Subunit Alpha

Functions: Functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA (PubMed:16289705). This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form a 43S pre-initiation complex (PubMed:16289705). Junction of the 60S ribosomal subunit to form the 80S initiation complex is preceded by hydrolysis of the GTP bound to eIF-2 and release of an eIF-2-GDP binary complex (PubMed:16289705). In order for eIF-2 to recycle and catalyze another round of initiation, the GDP bound to eIF-2 must exchange with GTP by way of a reaction catalyzed by eIF-2B (PubMed:16289705). EIF2S1/eIF-2-alpha is a key component of the integrated stress response (ISR), required for adaptation to various stress: phosphorylation by metabolic-stress sensing protein kinases (EIF2AK1/HRI, EIF2AK2/PKR, EIF2AK3/PERK and EIF2AK4/GCN2) in response to stress converts EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, leading to an attenuation of cap-dependent translation, while concomitantly initiating the preferential translation of ISR-specific mRNAs, such as the transcriptional activators ATF4 and QRICH1, and hence allowing ATF4- and QRICH1-mediated reprogramming (PubMed:19131336, PubMed:33384352)

The "EIF2S1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF2S1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets